ArticleScientific reports2025
Neuroprotective effects of melanins and melanin derivatives from Calvatia Craniiformis and Xylaria plebeja against Parkinsonian toxins.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fungal melanin as a bioactive biopolymer: structural diversity, oxidative stress modulation, anticancer mechanisms, and therapeutic perspectives.RSC advances · 2026Review
- Fungal Melanins as Potential Reactive Oxygen Species-Scavenging Neuroprotective Agents.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Fungal melanins have remarkable bioactivities, but their practical applications are limited, partly due to their hydrophobic nature. Melanin modification with amino acids was reported to improve their water solubility. This research aimed to extract, and modify the melanins from Calvatia craniiformis and Xylaria plebeja with arginine, and to evaluate their neuroprotective effects against Parkinsonian toxins. MTT assay showed that all melanins and melanin derivatives could protect SH-SY5Y neuroblastoma cells from 1 mM H2O2. Xylaria plebeja melanin and melanin derivative at 100 µg/mL increased the cell viability about 16.0% compared to the negative control, whereas C. craniiformis melanin and its modified form enhanced the cell viability by 18.4% and 8.3%, respectively and that of the positive control (20 µM resveratrol) was 35.5%. Regarding neuroprotective effects against MPTP, the positive control, C. craniiformis melanin, and modified melanin increased the cell viability with approximately 5.0%, but that of X. plebeja melanin and modified melanin were 13.0%. Both melanins and melanin derivatives from C. craniiformis and X. plebeja showed significant neuroprotective effects against H2O2. However, only X. plebeja melanin and modified melanin displayed significant neuroprotective effects against MPTP and therefore they would be potential materials for follow-up research in Parkinson's disease prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.